Cited by 723HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Open access

Venter, Willem D.F., Moorhouse, Michelle, Sokhela, Simiso, Fairlie, Lee, Mashabane, Nkuli, Masenya, Masebole, Serenata, Celicia, Akpomiemie, Godspower, Qavi, Ambar, Chandiwana, Nomathemba, Norris, Shane, Chersich, Matthew, Clayden, Polly, Abrams, Elaine, Arulappan, Natasha, Vos, Alinda, McCann, Kaitlyn, Simmons, Bryony, Hill, Andrew·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1902824

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries. METHODS: We conducted a 96-week, phase 3, investigator-led, open-label, randomized trial in South Africa, in which we compared a triple-therapy combination of emtricitabine (FTC) and DTG plus either of two tenofovir prodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against the local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group). Inclusion criteria included an age of 12 years or older, no receipt of ART in the previous 6 months, a creatinine clearance of more than 60 ml per minute (>80 ml per minute in patients younger than 19 years of age), and an HIV type 1 (HIV-1) RNA level of 500 copies or more per milliliter. The primary end point was the percentage of patients with a 48-week HIV-1 RNA level of less than 50 copies per milliliter (as determined with the Snapshot algorithm from the Food and Drug Administration; noninferiority margin, -10 percentage points). We report the primary (48-week) efficacy and safety data. RESULTS: A total of 1053 patients underwent randomization from February 2017 through May 2018. More than 99% of the patients were black, and 59% were female. The mean age was 32 years, and the mean CD4 count was 337 cells per cubic millimeter. At week 48, the percentage of patients with an HIV-1 RNA level of less than 50 copies per milliliter was 84% in the TAF-based group, 85% in the TDF-based group, and 79% in the standard-care group, findings that indicate that the DTG-containing regimens were noninferior to the standard-care regimen. The number of patients who discontinued the trial regimen was higher in the standard-care group than in the other two groups. In the per-protocol population, the standard-care regimen had equivalent potency to the other two regimens. The TAF-based regimen had less effect on bone density and renal function than the other regimens. Weight increase (both lean and fat mass) was greatest in the TAF-based group and among female patients (mean increase, 6.4 kg in the TAF-based group, 3.2 kg in the TDF-based group, and 1.7 kg in the standard-care group). No resistance to integrase inhibitors was identified in patients receiving the DTG-containing regimens. CONCLUSIONS: Treatment with DTG combined with either of two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the standard-care regimen. There was significantly more weight gain with the DTG-containing regimens, especially in combination with TAF, than with the standard-care regimen. (ADVANCE ClinicalTrials.gov number, NCT03122262.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1902824

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe
Mika Kivimaki, B., Kuosma, E., Ferrie, J. E., Luukkonen, R. A., Nyberg, S. T., Alfredsson, L. S., Batty, G. D., Brunner, E. J., Fransson, E. I., Goldberg, M., et al. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30074-9 · Cited by 695
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Sax, P. E., Pozniak, A., Montes, M., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 394
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
Zash, R., Makhema, J. M., & Shapiro, R. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1807653 · Cited by 379
Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens
Norwood, J., Turner, M. M., Bofill, C., Rebeiro, P. F., Shepherd, B. E., Bebawy, S. S., Hulgan, T., Raffanti, S. P., Haas, D. W., Sterling, T. R., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001525 · Cited by 285
Brief Report
Walmsley, S. L., Baumgarten, A., Berenguer, J., Felizarta, F., Florence, É., Khuong-Josses, M.-A., Kilby, J. M., Lutz, T., Podzamczer, D., Portilla, J., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000790 · Cited by 225
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Kanters, S., Vitória, M., Doherty, M. C., Socias, M. E., Ford, N. P., Forrest, J. I., Popoff, E., Bansback, N. J., Nsanzimana, S., Thorlund, K., et al. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30091-1 · Cited by 210
Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors
Bakal, D. R., Coelho, L. E., Luz, P. M., Clark, J. L., Boni, R. B. D., Cardoso, S. W., Veloso, V. G., Lake, J. E., & Grinsztejn, B. G. J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky145 · Cited by 188
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Wohl, D. A., Yazdanpanah, Y., Baumgarten, A., Clarke, A. E., Thompson, M., Brinson, C. C., Hagins, D. P., Ramgopal, M. N., Antinori, A., Wei, X., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30077-3 · Cited by 168

Flagged first, then by citations

Show all 31 references

Research works printed but not linked: 2

Doherty M. New directions in the 2015 WHO Consolidated ARV Guidelines: testing new directions in treatment and measuring impact. Presented at the Eighth International AIDS Society Conference Vancouver BC Canada July 19–22 2015.
Beyrer C, Pozniak A. HIV drug resistance. N Engl J Med 2018;378:875-875.29490186

Sorted by citations

Items 501–600 of 719

Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV
Lahiri, C. D., Mehta, C. C., Sykes, C., Weiser, S. D., Palella, F. J., Lake, J. E., Mellors, J. W., Gustafson, D., French, A. L., Adimora, A. A., et al. (2023) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2022.0185 · Cited by 2
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir
Hachey, D. M., van Woerden, I., Shiluama, R., & Singu, B. S. (2023) · International Journal of STD & AIDS · doi:10.1177/09564624231179767 · Cited by 2
Trends in body mass index in the pre-dolutegravir period in South Africa
van Ginkel, F., Barth, R. E., Tempelman, H. A., Klipstein‐Grobusch, K., Grobbee, D. E., Scheuermaier, K. D., Venter, F. W. D., & Vos, A. G. (2024) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v25i1.1523 · Cited by 2
Self-citation
Tenofovir alafenamide compared to tenofovir disoproxil fumarate, induces dysglycemia, and dyslipidemia in Wistar rats
Hurchund, R., Sibiya, S. S., Owaga, B. O., & Owira, P. M. O. (2024) · AIDS · doi:10.1097/qad.0000000000003987 · Cited by 2
Effect of Chronic Dolutegravir Administration on the Trace Amine Profile in Wistar Rats
Henning, N., Kellermann, T. A., & Smith, C. (2024) · Drugs in R&D · doi:10.1007/s40268-024-00484-4 · Cited by 2
The Real-World Impact of Long-Acting Injectable Cabotegravir-Rilpivirine on Weight and Renal Function
McNaboe, L. A., Ayala, Á., Kostka, J., Wakefield, D. B., & Chirch, L. M. (2025) · Cureus · doi:10.7759/cureus.78384 · Cited by 2
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study)
Iwuji, C. C., Waters, L. J., Milinkovic, A., Orkin, C. M., Fox, J., Post, F. A., Perry, N., Bruce, C., Dailey, N., To, Y., et al. (2025) · Virology Journal · doi:10.1186/s12985-025-02648-3 · Cited by 2
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites
Kityo, C. M., McCarthy, C., Koenig, S. P., Hughes, M. D., Wallis, C. L., Tsikhutsu, I., Munyanga, C., Mwelase, N., Schalkwyk, M. V., Marc, J. B., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf270 · Cited by 2
Incidence of metabolic syndrome in people with HIV who start dolutegravir based-regimen compared with bictegravir based-regimen after 48 weeks
Marín, J. A. M., Rodríguez-Evaristo, M. S., Cano-Díaz, A. L., Velázquez, G. E. S., González, S. T., Chaparro-Sánchez, A., Pompa-Mera, E. N., Cisneros, B. M., & Martínez, J. E. G. (2025) · AIDS · doi:10.1097/qad.0000000000004259 · Cited by 2
Aumento del peso nelle persone che vivono con infezione da HIV: ritorno al benessere o effetto indesiderato della terapia antiretrovirale?
Taramasso, L., & al., E. (2020) · JHA - Journal of HIV and Ageing · doi:10.19198/jha31488 · Cited by 2
Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults
Mésplède, T. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1902504 · Cited by 2
Management of Integrase Inhibitor-Associated Weight Gain: A Practical Clinical Approach
Wood, B. R. (2023) · Current Infectious Disease Reports · doi:10.1007/s11908-023-00803-x · Cited by 2
Dolutegravir quantification in wistar rat tissues following chronic administration
Henning, N., Smith, C., & Kellermann, T. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22541 · Cited by 2
Comorbidity and concomitant medication use in an integrase strand transfer inhibitor naïve cohort on first-line dolutegravir-based antiretroviral therapy
Hurbans, N., & Naidoo, P. (2024) · Pan African Medical Journal · doi:10.11604/pamj.2024.47.137.40726 · Cited by 2
Metabolic effects of switching to Biktarvy (B/F/ TAF ) in patients with HIV ‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate ( TDF ) or tenofovir alafenamide ( TAF ): The Metabic study
Busca‐Arenzana, C., Ortega‐González, D., Díaz‐Almirón, M., Montes, M., Martín‐Carbonero, L., Micán, R. E., Montejano, R., Ramos‐Ruperto, L., Valencia, E., Delgado‐Hierro, A., et al. (2024) · HIV Medicine · doi:10.1111/hiv.13659 · Cited by 2
Clinical considerations when switching antiretroviral therapy
Fernández, A., & Imaz, A. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2365826 · Cited by 2
Trends in body mass index for people with and without HIV: Pooled analysis of nationally-representative health surveys from 10 countries and 173,800 adults in Africa
Carrillo-Larco, R. M., Bulstra, C. A., Manne‐Goehler, J., Siedner, M. J., Johnson, L. C. M., Marconi, V. C., Chung, M. H., Venter, F., Kocher, E. L., Lalla‐Edward, S. T., et al. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003640 · Cited by 2
Self-citation
Initiation of Dolutegravir Versus Efavirenz on Viral Suppression and Retention at 6 months: A Regression Discontinuity Design
Zheng, A., Fox, M. P., Greener, R., Kileel, E. M., Bor, J. H., Venter, F., Pisa, P. T., Brennan, A. T., & Maskew, M. (2025) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003642 · Cited by 2
Non‐communicable disease (NCD) risk among people living with HIV in KwaZulu‐Natal, South Africa: evidence from a randomised trial of community‐based differentiated service delivery
Sahu, M., Szpiro, A. A., van Rooyen, H., Asiimwe, S. B., Shahmanesh, M., Roberts, D. A., Krows, M. L., Sausi, K., Sithole, N., Schaafsma, T. T., et al. (2025) · Journal of the International AIDS Society · doi:10.1002/jia2.26513 · Cited by 2
Antiretroviral Laboratory Monitoring and Implications for HIV Clinical Care in the Era of COVID-19 and Beyond
York, L. D., Fisher, J. M., Malladi, L., August, J., Ellis, K., Marquez, J. L., Kaveti, A., Khachatryan, M., Paz, M. K., Adams, M. D., et al. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2020.0263 · Cited by 2
Association between obesity and combination antiretroviral therapy (cART) adherence among persons with early-stage HIV infection initiating cART
Musinguzi, N., Stanford, F. C., Boatin, A. A., Orrell, C., Asiimwe, S. B., Siedner, M. J., Haberer, J. E., on behalf of the META team, Bwana, B. M., Amanyire, G., et al. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00837-y · Cited by 2
Principles of HIV Treatment
Pereira, L. F., Mgbako, O. U., Paulino-Woolridge, J., Figueiredo, M. E. C., & Carmen, T. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-80665-1_16 · Cited by 2
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
Hall, N., Allavena, C., Katlama, C., Jobert, A., Molina, J., Cua, É., Bani‐Sadr, F., Hocqueloux, L., Duvivier, C., Merrien, D., et al. (2022) · AIDS Research and Therapy · doi:10.1186/s12981-022-00428-5 · Cited by 2
Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks
Carr, M., Richardson, R., Tong, W. W. Y., Bloch, M. T., Baker, D., & Hoy, J. (2019) · AIDS · doi:10.1097/qad.0000000000002473 · Cited by 2
Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term
Boyce, C. L., Beck, I. A., Styrchak, S. M., Hardy, S. R., Wallner, J. J., Milne, R. S., Morrison, R. L., Shapiro, D. E., Joao, E. C., Mirochnick, M. H., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275254 · Cited by 2
Noninvasive Markers for Monitoring Fibrosis Regression After Hepatitis C Virus Cure: What Do They Promise?
Rockstroh, J. K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa698 · Cited by 2
Efficacy and Safety of Three Antiretroviral Therapy Regimens in Treatment-Naive African Adults Infected with HIV-2: A Randomised Controlled Phase II TrialPreprint
Eholié, S. P., Ekouévi, D. K., Chazallon, C., Charpentier, C., Messou, E., Diallo, Z., Zoungrana, J., Minga, A. K., Gueye, N. F. N., Hawerlander, D., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4605784 · Cited by 2
From Weight Gain to Heart Strain: HIV Antiretroviral Adverse Effect Management in Primary Care
Liu, H., Kehinde, G., Pugh, A., Cocohoba, J. M., & Hodge, C. K. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251347869 · Cited by 2
Uptake and predictors of viral load testing and viral suppression among people receiving antiretroviral therapy in mainland TanzaniaPreprint
Mutagonda, R. F., Lugoba, M. D., Mwakyomo, J., Sambu, V., Musiba, G., Mutayoba, B. K., Masuki, M. M., Njau, P. F., Maokola, W. M., & Sangeda, R. Z. (2026) · medRxiv · doi:10.64898/2026.03.11.26348142 · Cited by 2
Formalistic data and code availability policy in high-profile medical journals and pervasive policy-practice gaps in published articles: A meta-research study
Li, W., Liu, X., Zhang, Q., Shi, L., Zhang, J.-X., Zhang, X., Luan, J., Li, Y., Xu, T., Zhang, R., et al. (2026) · Accountability in Research · doi:10.1080/08989621.2025.2481943 · Cited by 1
Effects of antiretroviral therapy on glycemic and inflammatory indices in people living with HIV (PLWH)
Li, F., Liu, S., Baheti, R., Chen, T., Zhang, B., Wang, S., Peng, A., & Wan, J. (2024) · International Journal of STD & AIDS · doi:10.1177/09564624241283983 · Cited by 1
Qualitative study exploring reintegration of clinical trial participants with HIV to public health services in Johannesburg, South Africa
Nxumalo, S. T., Harris, B. N., Napoles, L., Oladimeji, K. E., & Lalla‐Edward, S. T. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084947 · Cited by 1
Dolutegravir regimens have transformed treatment, but ongoing drug resistance research is required to maintain success
van Zyl, G. U., Jennings, L., Rabie, H., & Orrell, C. (2024) · AIDS · doi:10.1097/qad.0000000000004099 · Cited by 1
Adipose tissue transcriptome in patients switching efavirenz or a protease inhibitor to raltegravir compared to people without HIV
Hanttu, A. M., Muniandy, M., van der Kolk, B. W., Lindgren, H., Yadav, B., Sutinen, J., & Pietiläinen, K. H. (2025) · AIDS · doi:10.1097/qad.0000000000004131 · Cited by 1
Cohort profile: Noncommunicable diseases and ideal cardiovascular health among people living with and without HIV in Zambia and Zimbabwe (NCDzz cohort)
Chihota, B., Mandiriri, A., Muula, G. K., Banda, E., Shamu, T., Bolton‐Moore, C., Chimbetete, C., Bosomprah, S., & Wandeler, G. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088706 · Cited by 1
Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir
Pickering, R. T., Asundi, A., Olson, A. J., Soden, K., Kuritzkes, D. R., & Lin, N. (2025) · Antiviral Therapy · doi:10.1177/13596535251314571 · Cited by 1
Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppressed adults living with HIV through 144 weeks
Rolle, C.-P., Garrett, J. S., Castano, J., Nguyen, V., Patel, K., Hinestrosa, F., & DeJesus, E. (2025) · Medicine · doi:10.1097/md.0000000000041728 · Cited by 1
Cord Blood Leptin Levels and Anthropometric Indices in Virally Suppressed HIV-Positive and HIV-Negative Mother–Singleton Newborn Pairs: A Comparative Analysis
Onubogu, C., Ugochukwu, E., & Okpara, H. (2025) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_605_24 · Cited by 1
Patterns of peri-gestational weight change among women living with HIV in Nigeria receiving dolutegravir compared to alternative antiretroviral regimens: a retrospective cohort study
Naimi, A. A., Chang, C. A., Rawizza, H. E., Olaifa, O., Ogunsola, O. O., Okonkwo, P., & Kanki, P. (2025) · AIDS Research and Therapy · doi:10.1186/s12981-025-00731-x · Cited by 1
Experience of a Nationwide implementation of single-tablet second-generation integrase inhibitors-based treatment in Mexico
Piñeirúa-Menéndez, A., Caro-Vega, Y. N., Mosqueda-Gómez, J. L., Ríos, S., Badial‐Hernández, F., Rosas, A. D. L. T., & Sierra-Madero, J. G. (2025) · IJID Regions · doi:10.1016/j.ijregi.2025.100645 · Cited by 1
Barriers to viral suppression in children aged 9 years or younger on dolutegravir-based antiretroviral therapy in Malawi, a mixed-methods study
Phiri, K., Hagström, C., Lungu, E., Balakasi, K. T., Songo, J., Makwaya, A., Smith, D., Worku, A., Hoffman, R. M., Phiri, S., et al. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004510 · Cited by 1
Effects of lifestyle modification counselling on weight and body composition among adults with overweight or obesity on antiretroviral therapy: a randomized controlled trial
Hirigo, A. T., Derbe, M., Yilma, D., Astatkie, A., & Debebe, Z. Y. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100184 · Cited by 1
Emergent HIV-1 Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens
Llibre, J. M., Ripamonti, D., Geretti, A. M., Martín-Iguacel, R., Sax, P. E., Gupta, R. K., Shafer, R. W., Schapiro, J., Kuritzkes, D. R., & Mésplède, T. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf471 · Cited by 1
The impact of cART on hepatic steatosis and fibrosis in treatment-naïve PLwHIV: A prospective cohort study
Özdemir, M. Ş., Özdemir, Y. E., Dogdas, A., Nuriyev, K., Şenkal, İ. V., Gündüz, A., Zerdali, E. Y., Kaymakoğlu, S., Mete, B., & Tabak, F. (2025) · International Journal of STD & AIDS · doi:10.1177/09564624251382627 · Cited by 1
Tenofovir-induced pathological neck of femur fractures in Human immunodeficiency virus-positive patients: A report of two cases with review of literature
Khompi, M. S., Pratap, A., Saidapur, S. K., & Hundekar, A. (2025) · Journal of Musculoskeletal Surgery and Research · doi:10.25259/jmsr_236_2025 · Cited by 1
Pharmacoeconomic perspectives on HIV: integrating data for long-term treatment and prevention
Mursal, M., Fatima, G., & Gushchina, Y. S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1716965 · Cited by 1
Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
Chen, G., Lee, N., Tsai, M.-S., Huang, S., Huang, M., Cl, L., Liou, B., Hung, T.-C., Lin, S.-P., Su, L., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf488 · Cited by 1
The Body Fat Percentage Rather Than the BMI Is Associated with the CD4 Count among HIV Positive Japanese Individuals
Shoji, K., Shirano, M., Konishi, M., Toyoshima, Y., Matsumoto, M., Goto, T., Kasamatsu, Y., Ichida, Y., Kagawa, Y., Kawabata, T., et al. (2022) · Nutrients · doi:10.3390/nu14030428 · Cited by 1
Emergence of Integrase Strand Transfer Inhibitors Resistance Mutations in Multidrug-Resistant Human Immunodeficiency Virus Strains Detected in Integrase Strand Transfer Inhibitors Naïve Indian Persons Living with Human Immunodeficiency Virus: A Report of Three Cases
Arora, S., Kisenjang, N., Ashta, K. K., & Raman, N. (2024) · Journal of Clinical Infectious Disease Society · doi:10.4103/cids.cids_43_24 · Cited by 1
‘DEFEND, DEFEND, DEFEND’: women’s HIV health activism, embodied feminist performance-making and radical kindness
Low, K. E., Petretti, S., Lowry, C. B., & Shaharuddin, M. (2025) · Medical Humanities · doi:10.1136/medhum-2024-013110 · Cited by 1
The influence of HIV on body composition and its relationship with physical function in mid-life women: a cross-sectional study from Zimbabwe
Breasail, M. Ó., Mesinovic, J., Madanhire, T., Mukwasi-Kahari, C., Ebeling, P. R., Simms, V. M., Ferrand, R. A., Ward, K. A., & Gregson, C. L. (2025) · Climacteric · doi:10.1080/13697137.2025.2496685 · Cited by 1
Comprehensive review on herbal remedies treatment for acquired immune deficiency syndrome (AIDS)
Verma, S., & Choudhary, S. S. (2025) · HIV & AIDS Review · doi:10.5114/hivar/188250 · Cited by 1
Initiation of dolutegravir vs. efavirenz on 12- and 24-month retention and viral suppression: a target trial emulation
Zheng, A., Brennan, A. T., Greener, R., Kileel, E. M., Bor, J. H., Venter, F., Murray, E. J., Pisa, P. T., Goeieman, B., Fox, M. P., et al. (2025) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2025.2557628 · Cited by 1
Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional study
Zhang, F., Cai, W., Wu, H., Ma, P., Zhao, Q., Wei, H., Lu, H., Wang, H., He, S., Zhu, C., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04376-5 · Cited by 1
Changes in Body Mass Index in Children and Adolescents Living With Human Immunodeficiency Virus in Europe and Thailand Starting Dolutegravir
Chappell, E., Crichton, S. L., Collins, I. J., Valle, G. D., Duff, C., Edgar, K., Giaquinto, C., Jackson, C., Judd, A., Mangiarini, L., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf640 · Cited by 1
Intersecting Burdens: Type 2 Diabetes Diagnosis, Risk, and Pharmacological Management Among People Living With HIV
Arnold, R., Fischetti, B., & Longo, M. (2025) · Journal of Pharmacy Practice · doi:10.1177/08971900251394121 · Cited by 1
Absorption, distribution, metabolism, excretion and mass balance of ainuovirine, a non-nucleoside reverse transcriptase inhibitor in humans
Wu, Y., Ma, S., Yun, X., He, F., Huang, G., Qin, H., Miao, L., & Zhang, H. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107471 · Cited by 1
Recent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic
Brüssow, H. (2026) · Microbial Biotechnology · doi:10.1111/1751-7915.70317 · Cited by 1
Virological and Immunological Outcomes of TLD and TLE Regimens as First-Line Therapy in Antiretroviral-Naive Adults: A Retrospective Cohort Study
Mengistie, B. T., Yassin, K. S., Kinfe, R. A., Belachew, R. S., Gelan, A. A., Hailemariam, C. M., Tesfay, R. H., Mengistie, C. T., Teferi, M., & Gubai, Z. Y. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02293-z · Cited by 1
Changes in Metabolic Parameters After Switching From Efavirenz to Dolutegravir-Based Regimen: A Cohort Study in Thai People Living With HIV
Chongyangyuenvong, P., & Kiertiburanakul, S. (2026) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/23259582261432459 · Cited by 1
Hematological Profiles of Newly Diagnosed Hiv Patients Initiated on Dolutegravir-based Therapy at the University of Nigeria Teaching Hospital, Enugu
Chima, O. K., Chukwurah, E. F., Ukwah, B. N., Usanga, V. U., Appiah, S. K., & Nkansah, C. (2025) · Journal of Clinical Haematology · doi:10.33696/haematology.6.070 · Cited by 1
Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study
Han, N., Loosli, T., Sauermann, M., Çelikağ, İ., Anderegg, N., Baye, B. C., Bolton‐Moore, C., Buzaalirwa, L., Byakwaga, H., Chimbetete, C., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag088 · Cited by 1
Comparison Of Clinical Stadium Changes And Immunologic Parameter Of Adult HIV patients With Dolutegravir And Efavirenz Based Antiretroviral Therapy
Zuhdi, M. N., Halim, R., Alimuddin, S., Bakri, S., Iskandar, H., & Zainuddin, A. (2026) · F1000Research · doi:10.12688/f1000research.179310.1 · Cited by 1
Age and CD4+ T cell counts are inversely associated with HIV drug resistance mutations in treatment naive female sex workers
Mulinge, M. M., Oluoch, J. O., Abisi, H. K., Otieno, L. E., Anzala, O. A., Wamalwa, D. C., Nduati, R. W., Kimani, J., Herbeck, J. T., & McKinnon, L. R. (2023) · Medicine · doi:10.1097/md.0000000000034060 · Cited by 1
Breastfeeding Among Women Living With HIV in the Era of Lifelong ART: An Observational Multicountry Study in Eastern and Southern Africa
Taha, T. E., Bandala-Jacques, A., Yende‐Zuma, N., Violari, A., Stranix‐Chibanda, L., Atuhaire, P., Hanley, S., Gadama, L. A., Chinula, L., Dadabhai, S. S., et al. (2023) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003306 · Cited by 1
International AIDS society conference 2023 summary
Waters, L. J., Wada, Y. H., & Barber, T. (2023) · HIV Medicine · doi:10.1111/hiv.13563 · Cited by 1
New Horizons in Antiretroviral Drug Delivery Systems for HIV Management
dos Santos, K. A., Moreira, L. M. C. D. C., Soares‐Sobrinho, J. L., & Soares, M. F. D. L. R. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673306606240802111136 · Cited by 1
Occupational Syndemics in Farmworkers in the Cape Winelands, South Africa
Bulled, N. L. (2025) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed10070179 · Cited by 1
Long-term metabolic and safety profiles of tenofovir alafenamide and tenofovir disoproxil fumarate in ART-naive people living with HIV: a multicenter retrospective study using a mixed-effects model
Karabay, O., Vatan, A., Uçar, A., Yilmaz, I., Balta, N. C., Kantürk, A., Dumlu, R., Çağ, Y., Çaşkurlu, H., Şık, M. T., et al. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-01003-0 · Cited by 1
Decline in estimated glomerular filtration rate following substitution of Nevirapine-based regimen with Tenofovir-based regimen in Indonesia
Yunihastuti, E., Nugroho, P., Yusuf, M., Lastari, S. D., Harinda, F., Putri, T. K., Pane, M. R., Pratama, M. A., Yulianti, M., Widhani, A., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11710-y · Cited by 1
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine
Calza, L., Borderi, M., Colangeli, V., Esposito, F., Giglia, M., Bon, I., & Re, M. C. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2020.0167 · Cited by 1
Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor
Piacentini, D., Lanzafame, M., Rizzardo, S., Chiesi, S., Lattuada, E., Mehrabi, S., Zamboni, G. A., Mazzi, R., Tacconelli, E., & Vento, S. (2020) · International Journal of STD & AIDS · doi:10.1177/0956462420955075 · Cited by 1
Lipodystrophies acquises associées au VIH et à son traitement et complications cardiovasculaires associées (de la physiopathologie à la prise en charge)
Boccara, F., & Capeau, J. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.01.008 · Cited by 1
Weight and antiretrovirals: a new episode in a long series
Capeau, J. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00189-2 · Cited by 1
Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide
Schafer, J. J., Zimmerman, M., Walshe, C., Cerankowski, J., Shimada, A., & Keith, S. W. (2022) · Obesity · doi:10.1002/oby.23443 · Cited by 1
Human Immunodeficiency Virus
Wohl, D. A., & Prather, C. P. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108942751.025 · Cited by 1
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
Rahman, F., McLaughlin, T. A., Mesquita, P., Morin, J., Potvin, D., de Chantal, M., & Aberg, J. A. (2022) · Journal of Clinical and Translational Science · doi:10.1017/cts.2022.515 · Cited by 1
Two-drug antiretroviral regimens for HIV
Thornhill, J. P., Cromarty, B., Gaddie, J., Mushunje, S., & Ferrand, R. A. (2023) · BMJ · doi:10.1136/bmj-2022-071079 · Cited by 1
AIDS, DoençaEmergente Que Permanece
Grinsztejn, B. G. J., Jalil, E. M., & Veloso, V. G. (2023) · Anais da Academia Nacional de Medicina · doi:10.52130/27639878-aanm2023v194n2p56-75 · Cited by 1
HIV/AIDS : Antiretroviral Drugs
Geretti, A. M. (2020) · Wiley eBooks · doi:10.1002/9780470015902.a0028523 · Cited by 1
Cabotegravir – global access to long-acting pre-exposure prophylaxis for HIVPreprint
Pepperrell, T., Cross, S., & Hill, A. M. (2022) · Research Square · doi:10.21203/rs.3.rs-2198548/v1 · Cited by 1
Self-citation
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
Koethe, J. R. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf566 · Cited by 1
Circulating resistance to first-line HIV drug regimens
Iwuji, C. C., & Siedner, M. J. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30374-1
„Human-immunodeficiency-virus“-Infektion im Alter
Bogner, J. R. (2019) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-019-01669-2
Response to Noe, Oldenbuettel and Jaeger
Shafran, S. D., & Perri, G. D. (2019) · HIV Medicine · doi:10.1111/hiv.12835
Not all is perfect with Tenofovir alafenamide
Noé, S., Jonsson‐Oldenbüttel, C., & Jaeger, H. (2019) · HIV Medicine · doi:10.1111/hiv.12832
Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study
Raffi, F., Gaultier, A., Pozniak, A., Molina, J., Jessen, H. K., Antinori, A., Soria, A., Cavellec, M., Thuaut, A. L., Ningre, M., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa056
High Baseline Viremia: An Achilles Heel for Integrase Inhibitor–Based Antiretroviral Therapy?
McCluskey, S. M., & Marconi, V. C. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1620
Tenofovir alafenamide versus tenofovir disoproxil fumarate: integrating systematic review findings into practice and policy
Wood, B. R. (2020) · AIDS · doi:10.1097/qad.0000000000002672
Benefícios terapêuticos do agulhamento seco em adultos com dor lombar crônica
Leal, L. M. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200005
EFEITOS DA EXPOSIÇÃO AO CÁDMIO SOBRE A PRESSÃO ARTERIAL E A CONTRATILIDADE MIOCÁRDICA
Toscano, C. M., Schereider, I. R. G., de Batista, P. R., & Vassallo, D. V. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200008
EXPOSIÇÃO AO CÁDMIO COMO UM PROBLEMA DE SAÚDE PÚBLICA E SEU EFEITO SOBRE VASOS DE RESISTÊNCIA
de Batista, P. R., Schereider, I. R. G., Toscano, C. M., & Vassallo, D. V. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200011
INFLUÊNCIA DA LESÃO MEDULAR E TEMPO DE CADEIRA DE RODAS NA FORÇA MUSCULAR RESPIRATÓRIA E TOSSE
Batalha, T. R., Ambrosim, M. F., Batista, R. R. B., & Lourenço, C. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200012
ESTUDO COMPARATIVO ENTRE DOLUTEGRAVIR E EFAVIRENZ EM ESQUEMAS DE TERAPIA ANTIRRETROVIRAL NO TRATAMENTO DO HIV: ADESÃO, EFICÁCIA E EFEITO ADVERSOS
Campanati, S. S. E., Pereira, M. R. T., Werner, L. A., & Neto, L. F. D. S. P. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200007
ASSOCIAÇÃO ENTRE QUALIDADE DE VIDA E MORTALIDADE EM PACIENTES COM INSUFICIÊNCIA CARDÍACAASSOCIAÇÃO ENTRE QUALIDADE DE VIDA E MORTALIDADE EM PACIENTES COM INSUFICIÊNCIA CARDÍACA
Barbosa, R. R., Torres, L. D., Silva, M. C. P. D., Miranda, C. C., Colodete, I. A., Croteletti, A., Jacques, T. D. M., Serpa, R. G., Calil, O. A., & Barbosa, L. F. M. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200003
ESTUDO PILOTO DO PROJETO RICASA: SEGUIMENTO TARDIO DE PACIENTES HOSPITALIZADOS POR INSUFICIÊNCIA CARDÍACA DESCOMPENSADA
Belloti, V. L., Bobbio, R. D., Lima, P. D., Serpa, R. G., Calil, O. A., Barbosa, L. F. M., & Barbosa, R. R. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200006
TRANSTORNO NEUROCOGNITIVO LEVE: COMPARAÇÃO DE DOIS TESTES DE AVALIAÇÃO COGNITIVA
Tatagiba, L. A. B., de Oliveira, T. C., Loureiro, D. A., Gomes, P. T. V., Benevenut, R., Devens, L. T., Tieppo, A., & Morelato, R. L. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200016
Ausência de associação DO SNP+45T>G COM DOENÇAS CARDIOVASCULARES EM PACIENTES OBESOS
do Nascimento, G. S., Pinto, I. A., da Fonseca, S. R., de Carvalho, P. S., Rosseto, A. S., Coimbra, J. B., de Freitas, J. V., & Errera, F. I. V. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200004
RELAÇÃO ENTRE DERIVADAS DE PARÂMETROS DO HEMOGRAMA COM MORTALIDADE E TEMPO DE INTERNAÇÃO DE DOENTES CRÍTICOS
Baptista, F. D. S., Bellote, F. L., Ferreira, F., Bellon, C. T. A., Oliveira, J. P. D. O. E., Mattede, M. D. G. S., & de Morais, A. A. C. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200014
EFEITOS AGUDOS E CRÔNICOS DO CÁDMIO SOBRE VASOS DE CONDUTÂNCIA
Schereider, I. R. G., Toscano, C. M., de Batista, P. R., Simões, M. R., & Vassallo, D. V. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200010

Authors: Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., Norris, S., Chersich, M., Clayden, P., Abrams, E., Arulappan, N., Vos, A., McCann, K., Simmons, B., & Hill, A.
Affiliations: From Ezintsha (W.D.F.V., M. Moorhouse, S.S., N.M., C.S., G.A., N.C., N.A., A.V.), Wits Reproductive Health and HIV Institute, Faculty of Health Sciences (W.D.F.V., M. Moorhouse, S.S., L.F., N.M., M. Masenya, C.S., G.A., N.C., M.C., N.A., A.V.), and the South African Medical Research Council Developmental Pathways for Health Research Unit, Department of Pediatrics, School of Clinical Medicine, Faculty of Health Sciences (S.N.), University of the Witwatersrand, Johannesburg; the Faculty of Medicine,...
South African Medical Research Council (ZA)
ORCID: Venter, Willem D.F.
Moorhouse, Michelle
Sokhela, Simiso
Fairlie, Lee
Mashabane, Nkuli
Masenya, Masebole
Serenata, Celicia
Akpomiemie, Godspower
Qavi, Ambar
Chandiwana, Nomathemba
Norris, Shane
Chersich, Matthew
Clayden, Polly
Abrams, Elaine
Arulappan, Natasha
Vos, Alinda
McCann, Kaitlyn
Simmons, Bryony
Hill, Andrew
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-08-29
Volume: 381
Issue: 9
Pages: 803-815
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1902824
OpenAlex: W2962964639
Cited by: 723
References: 31
Citations by year: 2026: 65 · 2025: 84 · 2024: 117 · 2023: 110 · 2022: 90 · 2021: 112 · 2020: 120 · 2019: 25
FWCI: 66.47
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
ePrints Soton (University of Southampton) (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion)
Funders: UNITAID (2016-07-Wits RHI)
U.S. Agency for International Development (AID-OAA-A-15-00069)
South African Medical Research Council
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: dolutegravir, tenofovir alafenamide, tenofovir disoproxil fumarate, HIV-1 infection, antiretroviral therapy, triple therapy, emtricitabine, efavirenz, non-inferiority, viral suppression, treatment discontinuation, low- and middle-income countries, South Africa
MeSH terms: Dolutegravir, Adenine, Adolescent, Adult, Drug Therapy, Combination, Female, Heterocyclic Compounds, 3-Ring, Humans, Male, Middle Aged, Oxazines, Phosphorous Acids, Piperazines, Pregnancy, Pregnancy Complications, Infectious, Prodrugs, Pyridones, RNA, Viral, Uracil, HIV-1, Bone Density, HIV Infections, CD4 Lymphocyte Count, HIV Integrase Inhibitors, Viral Load, Anti-Retroviral Agents, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks